Phase 2 Readout~quarter

Phase 2 Readout: envudeucitinib

Indication
moderate-to-severe plaque psoriasis

Other upcoming events for ALMS

Phase 2 ReadoutPhase 2 Readout: envudeucitinib
Phase 3 ReadoutPhase 3 Topline: An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Sa

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar